Review



human breast cancer stem cell complete growth medium  (Celprogen Inc)


Bioz Verified Symbol Celprogen Inc is a verified supplier
Bioz Manufacturer Symbol Celprogen Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Celprogen Inc human breast cancer stem cell complete growth medium
    Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806 or <t>breast</t> <t>cancer</t> <t>stem</t> cells were treated with fresh <t>medium</t> that contained different FND-4b concentrations (0, 1, 2.5, 5, 10, and 20 μM) for 24 h. Western blot analysis was then performed for phosphorylated and total forms of AMPKα, ACC, and S6 as well as cyclin D1 and cleaved PARP. Beta-actin was used as the loading control. Treatment of the HCC-1806 <t>cell</t> line was repeated to confirm the spike in AMPKα activation at the 5 μM dosage with subsequent decreases at higher concentrations.
    Human Breast Cancer Stem Cell Complete Growth Medium, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+breast+cancer+stem+cell+complete+growth+medium/pmc06420029-46-0-10?v=Celprogen+Inc
    Average 90 stars, based on 3 article reviews
    human breast cancer stem cell complete growth medium - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Induction of AMPK activation by N , N’- diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers"

    Article Title: Induction of AMPK activation by N , N’- diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0209392

    Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806 or breast cancer stem cells were treated with fresh medium that contained different FND-4b concentrations (0, 1, 2.5, 5, 10, and 20 μM) for 24 h. Western blot analysis was then performed for phosphorylated and total forms of AMPKα, ACC, and S6 as well as cyclin D1 and cleaved PARP. Beta-actin was used as the loading control. Treatment of the HCC-1806 cell line was repeated to confirm the spike in AMPKα activation at the 5 μM dosage with subsequent decreases at higher concentrations.
    Figure Legend Snippet: Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806 or breast cancer stem cells were treated with fresh medium that contained different FND-4b concentrations (0, 1, 2.5, 5, 10, and 20 μM) for 24 h. Western blot analysis was then performed for phosphorylated and total forms of AMPKα, ACC, and S6 as well as cyclin D1 and cleaved PARP. Beta-actin was used as the loading control. Treatment of the HCC-1806 cell line was repeated to confirm the spike in AMPKα activation at the 5 μM dosage with subsequent decreases at higher concentrations.

    Techniques Used: Western Blot, Activation Assay

    (A) Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806, or breast cancer stem cells were grown in medium containing 0 or 5 μM FND-4b for 72 h followed by cell counting. (B) The same procedure described in (A) was followed with the exception of growing cells in medium containing 0 or 1 mM AICAR instead. (C) MCF-7, T-47D, MDA-MB-231, and HCC-1806 cells were grown in medium containing different concentrations of FND-4b (0, 2.5, 5, 10, and 20 μM) for 72 h before SRB growth assays were performed. Data are presented as mean ± SD from experiments performed in triplicate (cell counting) or sextuplicate (SRB assays) and are representative of three independent experiments. * indicates p-value < 0.01.
    Figure Legend Snippet: (A) Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806, or breast cancer stem cells were grown in medium containing 0 or 5 μM FND-4b for 72 h followed by cell counting. (B) The same procedure described in (A) was followed with the exception of growing cells in medium containing 0 or 1 mM AICAR instead. (C) MCF-7, T-47D, MDA-MB-231, and HCC-1806 cells were grown in medium containing different concentrations of FND-4b (0, 2.5, 5, 10, and 20 μM) for 72 h before SRB growth assays were performed. Data are presented as mean ± SD from experiments performed in triplicate (cell counting) or sextuplicate (SRB assays) and are representative of three independent experiments. * indicates p-value < 0.01.

    Techniques Used: Cell Counting



    Similar Products

    human breast cancer stem cell complete growth medium  (Celprogen Inc)
    90
    Celprogen Inc human breast cancer stem cell complete growth medium
    Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806 or <t>breast</t> <t>cancer</t> <t>stem</t> cells were treated with fresh <t>medium</t> that contained different FND-4b concentrations (0, 1, 2.5, 5, 10, and 20 μM) for 24 h. Western blot analysis was then performed for phosphorylated and total forms of AMPKα, ACC, and S6 as well as cyclin D1 and cleaved PARP. Beta-actin was used as the loading control. Treatment of the HCC-1806 <t>cell</t> line was repeated to confirm the spike in AMPKα activation at the 5 μM dosage with subsequent decreases at higher concentrations.
    Human Breast Cancer Stem Cell Complete Growth Medium, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+breast+cancer+stem+cell+complete+growth+medium/pmc06420029-46-0-10?v=Celprogen+Inc
    Average 90 stars, based on 1 article reviews
    human breast cancer stem cell complete growth medium - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    human breast cancer stem cell complete growth media with serum  (Celprogen Inc)
    90
    Celprogen Inc human breast cancer stem cell complete growth media with serum
    Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806 or <t>breast</t> <t>cancer</t> <t>stem</t> cells were treated with fresh <t>medium</t> that contained different FND-4b concentrations (0, 1, 2.5, 5, 10, and 20 μM) for 24 h. Western blot analysis was then performed for phosphorylated and total forms of AMPKα, ACC, and S6 as well as cyclin D1 and cleaved PARP. Beta-actin was used as the loading control. Treatment of the HCC-1806 <t>cell</t> line was repeated to confirm the spike in AMPKα activation at the 5 μM dosage with subsequent decreases at higher concentrations.
    Human Breast Cancer Stem Cell Complete Growth Media With Serum, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+breast+cancer+stem+cell+complete+growth+medium/custom%40m36102-29s%4029174970?v=Celprogen+Inc
    Average 90 stars, based on 1 article reviews
    human breast cancer stem cell complete growth media with serum - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806 or breast cancer stem cells were treated with fresh medium that contained different FND-4b concentrations (0, 1, 2.5, 5, 10, and 20 μM) for 24 h. Western blot analysis was then performed for phosphorylated and total forms of AMPKα, ACC, and S6 as well as cyclin D1 and cleaved PARP. Beta-actin was used as the loading control. Treatment of the HCC-1806 cell line was repeated to confirm the spike in AMPKα activation at the 5 μM dosage with subsequent decreases at higher concentrations.

    Journal: PLoS ONE

    Article Title: Induction of AMPK activation by N , N’- diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers

    doi: 10.1371/journal.pone.0209392

    Figure Lengend Snippet: Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806 or breast cancer stem cells were treated with fresh medium that contained different FND-4b concentrations (0, 1, 2.5, 5, 10, and 20 μM) for 24 h. Western blot analysis was then performed for phosphorylated and total forms of AMPKα, ACC, and S6 as well as cyclin D1 and cleaved PARP. Beta-actin was used as the loading control. Treatment of the HCC-1806 cell line was repeated to confirm the spike in AMPKα activation at the 5 μM dosage with subsequent decreases at higher concentrations.

    Article Snippet: Human breast cancer stem cell complete growth medium was from Celprogen (Torrance, CA).

    Techniques: Western Blot, Activation Assay

    (A) Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806, or breast cancer stem cells were grown in medium containing 0 or 5 μM FND-4b for 72 h followed by cell counting. (B) The same procedure described in (A) was followed with the exception of growing cells in medium containing 0 or 1 mM AICAR instead. (C) MCF-7, T-47D, MDA-MB-231, and HCC-1806 cells were grown in medium containing different concentrations of FND-4b (0, 2.5, 5, 10, and 20 μM) for 72 h before SRB growth assays were performed. Data are presented as mean ± SD from experiments performed in triplicate (cell counting) or sextuplicate (SRB assays) and are representative of three independent experiments. * indicates p-value < 0.01.

    Journal: PLoS ONE

    Article Title: Induction of AMPK activation by N , N’- diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers

    doi: 10.1371/journal.pone.0209392

    Figure Lengend Snippet: (A) Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806, or breast cancer stem cells were grown in medium containing 0 or 5 μM FND-4b for 72 h followed by cell counting. (B) The same procedure described in (A) was followed with the exception of growing cells in medium containing 0 or 1 mM AICAR instead. (C) MCF-7, T-47D, MDA-MB-231, and HCC-1806 cells were grown in medium containing different concentrations of FND-4b (0, 2.5, 5, 10, and 20 μM) for 72 h before SRB growth assays were performed. Data are presented as mean ± SD from experiments performed in triplicate (cell counting) or sextuplicate (SRB assays) and are representative of three independent experiments. * indicates p-value < 0.01.

    Article Snippet: Human breast cancer stem cell complete growth medium was from Celprogen (Torrance, CA).

    Techniques: Cell Counting